RP implant moves into the next phase

Neurotech Pharmaceuticals has begun enrolment for two Phase II/III clinical trials of NT-501; it's lead Encapsulated Cell Technology (ECT) product for the treatment for retinitis pigmentosa (RP).

Neurotech Pharmaceuticals has begun enrolment for two Phase II/III clinical trials of NT-501; it's lead Encapsulated Cell Technology (ECT) product for the treatment for retinitis pigmentosa (RP).

NT-501 is an intraocular, polymer implant that contains human retinal epithelial cells genetically modified to secrete Ciliary Neurotrophic Factor (CNTF). The implant is designed to continuously release CNTF directly into the back of the eye.

The Phase II/III randomized, double-masked, sham-controlled, dose ranging studies will evaluate the safety and efficacy of the implant at 14 centres across the US.